Interacciones medicamentosas entre terapia antirretroviral y terapia biológica en paciente con enfermedad por VIH y artritis reumatoide: una revisión de la literatura

Linda Estefanía Navarrete Motta

doi:10.61182/rnavmed.v6n2a1

Authors

Linda Estefanía Navarrete Motta Facultad de medicina, Pontificia Universidad Javeriana, Bogotá, Colombia. https://orcid.org/0000-0003-3596-9906

DOI:

https://doi.org/10.61182/rnavmed.v6n2a1

Keywords:

HIV, rheumatoid arthritis, drug interactions, biologic therapy

Abstract

The simultaneous presence of human immunodeficiency virus and rheumatoid arthritis in patients poses challenges for public health. From the pharmacological point of view, it is pertinent to observe the interactions between the drugs involved in treating them, little studied so far. This study proposes a narrative review of the medical literature in different databases, with publication filters such as time (1997-2013) and treatment of the central theme. Twenty-two articles with such characteristics were analyzed. The literature reviewed does not report interactions between drugs to treat rheumatoid arthritis and HIV. Studies are still needed to identify such drug-drug interactions.

Author Biography

Linda Estefanía Navarrete Motta, Facultad de medicina, Pontificia Universidad Javeriana, Bogotá, Colombia.

M.D. Specialist in internal medicine. Specialist in epidemiology.

References

Peña E, Prieto L, Cárdenas V. Terapia biológica para el tratamiento de pacientes con artritis reumatoide refractaria [Internet]. 2013 [citado el 28 de noviembre de 2019]. Disponible en: https://docs.bvsalud.org/biblioref/2017/11/875718/biologicos_ar_11022014-vf.pdf

DeSimone JA. Inflammatory Reactions in HIV-1–Infected Persons after Initiation of Highly Active Antiretroviral Therapy. Ann Intern Med. 2000;133(6):447–54. https://doi.org/10.7326/0003-4819-133-6-200009190-00013

Walker UA, Tyndall A, Daikeler T. Rheumatic conditions in human immunodeficiency virus infection. Rheumatology. 2008;47(7):952–9. https://doi.org/10.1093/rheumatology/ken132

Reveille JD, Williams FM. Rheumatologic complications of HIV infection. Best Pract Res Clin Rheumatol. 2006;20(6):1159–79. https://doi.org/10.1016/j.berh.2006.08.015

Cohen O, FA WD. The immunopathogenesis of HIV infection. En: Paul W, editor. Fundamental Immunology. 4a ed. Philadelphia: Lippincott-Raven Publishers; 1999. p. 1455–98.

Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, et al. CC CKR5: A RANTES, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1. Science (1979). 1996;272(5270):1955–8. https://doi.org/10.1126/science.272.5270.1955

Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor. Science (1979). 1996;272(5263):872–7. https://doi.org/10.1126/science.272.5263.872

Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al. Causes of death among HIV-infected patients in France in 2010 (national survey). AIDS. 2014;28(8):1181–91. https://doi.org/10.1097/qad.0000000000000222

Morlat P (Ed.). Prise en charge du VIH – Recommandations du groupe d’experts [Internet]. Recommandations du groupe d’experts. Paris: CNS & ANRS; 2017. Disponible en: www.cns.sante.fr/wp-content/uploads/2017/10/experts-vih_cancers.pdf

Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. The Lancet. 2008;372(9635):293–9. https://doi.org/10.1016/s0140-6736(08)61113-7

UNAIDS. Global Report [Internet]. Geneva: World Health Organization; 2012 [citado el 28 de noviembre de 2019]. Disponible en: https://www.unaids.org/sites/default/files/media_asset/20121120_UNAIDS_Global_Report_2012_with_annexes_en_1.pdf

Ministerio de Salud y Protección Social & Fondo de Población de las Naciones Unidas. Guía de práctica clínica (GPC) basada en la evidencia científica para la atención de la infección por VIH/Sida en adolescentes (con 13 años de edad o más) y adultos [Internet]. Bogotá: UNFPA; 2014 [citado el 28 de noviembre de 2019]. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/CA/gpc-completa-evidencia-cientifica-vih-sida-adolescentes-adultos.pdf

Tuset M, Miró JM, Codina CRJ. Guía de interacciones farmacológicas en VIH. Barcelona: Aurores y Bristol-Myers; 2002.

Tuset M, Miró JM, Codina C, Blanco J. L, Soy D, Sarasa M. Interacciones de los fármacos antirretrovirales. En: Gatell JM, Clotet B, Mallolas J, Miró JM, Podzamczer D, editores. Guía práctica del sida: clínica, diagnóstico y tratamiento. Barcelona: Ediciones Masson; 2002. p. 555–93.

Escobar I, Ortega L (Coord.). 5° Seminario de Atención Farmacéutica: Ponencias. Madrid: SEFH; 2005.

Tuset M. Interacciones medicamentosas entre los antirretrovirales y los antituberculosos. Rev Esp Sanid Penit. 1999;1(4):28–44.

Nedwin GE, Naylor SL, Sakaguchi AY, Smith D, Jarrett-Nedwin J, Pennica D, et al. Human Lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization. Nucleic Acids Res. 1985;13(17):6361–73. https://doi.org/10.1093%2Fnar%2F13.17.6361

Baggiolini M. Chemokines and leukocyte traffic. Nature. 1998;392(6676):565–8. https://doi.org/10.1038/33340

Salgado E, Maneiro JR. Nuevos tratamientos en artritis reumatoide. Med Clin (Barc). 2014;143(10):461–6.

European Medicines Agency. Humira (adalimumab) [Internet]. Amsterdam; 2020 [citado el 28 de noviembre de 2019]. Disponible en: https://www.ema.europa.eu/en/documents/overview/humira-epar-medicine-overview_es.pdf

Tornero Molina J, Ballina García FJ, Calvo Alén J, Caracuel Ruiz MÁ, Carbonell Abelló J, López Meseguer A, et al. Recomendaciones para el uso del metotrexato en artritis reumatoide: incremento y reducción de dosis y vías de administración. Reumatol Clin. 2015;11(1):3–8.

Ramos A. Infecciones en el paciente inmunodeficiente. ¿Qué papel tienen los fármacos? Reumatol Clin. 2008;4:1–6.

León Regal ML, Alvarado Borges A, De Armas García JO, Miranda Alvarado L, Varens Cedeño JA, Cuesta del Sol JÁ. Respuesta inflamatoria aguda. Consideraciones bioquímicas y celulares. Revista Finlay [Internet]. 2015 [citado el 28 de noviembre de 2019];5(1):47–62. Disponible en: http://scielo.sld.cu/scielo.php?pid=S2221-24342015000100006&script=sci_arttext

Pasut G. Pegylation of Biological Molecules and Potential Benefits: Pharmacological Properties of Certolizumab Pegol. BioDrugs. 2014;28(S1):15–23.

Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor α agents. Inflamm Bowel Dis. 2007;13(11):1323–32. https://doi.org/10.1002/ibd.20225

Howson JMM, Walker NM, Clayton D, Todd JA. Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA‐B and HLA‐A. Diabetes Obes Metab. 2009;11(s1):31–45.

Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M. Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis. PLoS One. 2012;7(1):1–14.

Schiff M. Abatacept treatment for rheumatoid arthritis. Rheumatology. 2011;50(3):437–49. https://doi.org/10.1093/rheumatology/keq287

Boyd M, Pett S. Experimental and clinical pharmacology: HIV fusion inhibitors: a review. Aust Prescr. 2008;31(3):66–9.

Beaird SL. HMG-CoA Reductase Inhibitors: Assessing Differences in Drug Interactions and Safety Profiles. Journal of the American Pharmaceutical Association (1996). 2000;40(5):637–44.

Herman RJ. Drug interactions and the statins. CMAJ. 1999;161(10):1281–6. https://pubmed.ncbi.nlm.nih.gov/10584091

Frassetto LA, Baloum M, Roland ME, Carlson L, Stock PBL. Two-year Evaluation of the Interactions between Antiretroviral Medication and Cyclosporine in HIV+ Liver and Kidney Transplant Recipients (abstract 540). En: 10th Conference on Retroviruses and Opportunistic Infections. Boston: CROI; 2003.

Schvarcz R, Rudbeck G, Söderdahl G, Ståhle L. Interaction between Nelfinavir and Tacrolimus After Orthoptic Liver Transplantation in a Patient Coinfected with HIV And Hepatitis C Virus (HCV). Transplantation. 2000;69(10):2194–5. https://doi.org/10.1097/00007890-200005270-00041

Gerber JG, Rosenkranz S, Segal Y, Aberg J, D’Amico R, Mildvan D, et al. Effect of Ritonavir/Saquinavir on Stereoselective Pharmacokinetics of Methadone: Results of AIDS Clinical Trials Group (ACTG) 401. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2001;27(2):153–60. https://doi.org/10.1097/00126334-200106010-00010

Moreno S, Podzamczer D, Blázquez R, Iribarren JA, Ferrer E, Reparaz J, et al. Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin. AIDS. 2001;15(9):1185–7. https://doi.org/10.1097/00002030-200106150-00018